FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease
Madrigal Pharmaceuticals’ NASH drug won an accelerated approval on Thursday, becoming the first treatment for a liver disease that for years has vexed scientists and investors.
The medication, resmetirom, was approved under the brand name Rezdiffra for patients with stage 2 and 3 fibrosis. It’s expected to be available in April, according to Madrigal. While the FDA described the disease as NASH in its label, it is now often referred to as metabolic dysfunction-associated steatohepatitis (MASH).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
